Dynamics of serum concentrations of antibodies to infliximab: a new approach for predicting secondary loss of response in inflammatory bowel diseases

BACKGROUND: Antibodies to infliximab (ATI) in serum are associated with secondary loss of response (LOR) to infliximab (IFX) therapy in patients with inflammatory bowel disease (IBD). However, feasible ATI-related predictors of therapy success are lacking and knowledge about individual ATI dynamics...

Descripción completa

Detalles Bibliográficos
Autores principales: Grasmeier, Melina K., Langmann, Anna F., Langmann, Peter, Treiber, Matthias, Thaler, Markus A., Luppa, Peter B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381421/
https://www.ncbi.nlm.nih.gov/pubmed/34434255
http://dx.doi.org/10.1177/17562848211037849

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381421/
https://www.ncbi.nlm.nih.gov/pubmed/34434255
http://dx.doi.org/10.1177/17562848211037849

Ejemplares similares